The first-ever pill for treating postpartum depression, approved by the Food and Drug Administration in August 2023, has provided relief for thousands of women since its market launch in December 2023. Drugmaker Sage Therapeutics reports that more than 10,000 women in the United States have been treated with the medication, known as Zurzuvae, representing a significant breakthrough in targeted postpartum mental health care.
A Mother’s Journey
One North Texas mother credits Zurzuvae with helping her through what she describes as the hardest year of her life. Kristina Leos, a mother of three, experienced postpartum depression for 10 months following her daughter Victoria’s birth in March 2023. Despite starting on antidepressants shortly after delivery, Leos found herself in a cycle where increased doses provided temporary relief before symptoms returned. The struggle became so severe she considered hospitalization. A women’s health psychiatrist eventually diagnosed her with partially treatment-resistant postpartum depression, requiring a fundamentally different approach to treatment.
How Zurzuvae Works
Zurzuvae is taken once daily at night for 14 days, with benefits appearing as quickly as three days according to patient reports. The medication targets receptors in the brain that manage mood and stress, which depend on a steroid whose levels become depleted in women with postpartum depression. Leos began the medication on New Year’s Day 2024 and noticed improvement within her first three days. “It just changed my life so much,” she recalled, describing the transformation from hopelessness to engagement with her children.
Practical Considerations
For Leos, the treatment involved specific precautions: she was advised not to breastfeed while taking the medication, but she managed by pumping ahead of time and freezing milk, then using formula while on the two-week course. The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infections. Zurzuvae is covered for approximately 95% of insured commercial and Medicaid patients, with most plans having no step edits or complex prior authorizations, making access more feasible for many families.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.nbcdfw.com/news/health/mom-credits-breakthrough-ppd-drug-zurzuvae/3852562/